Fenwick Represents ArrowMark Partners in IP Due Diligence of Precision BioSciences’ $110 Million Series B Financing

Fenwick & West represented ArrowMark Partners, an employee-owned asset manager with specialized expertise in alternative credit and growth equity asset classes, in the intellectual property due diligence aspect of its $110 million Series B investment in Precision Biosciences, a leading startup in the development of therapeutics and services based on genomic molecular biology designed to eliminate cancers. ArrowMark Partners led the round and was joined by new investors, Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, and entities affiliated with Leerink Partners. Existing investors, venBio, F-Prime, RA Capital Management, Amgen Ventures, Osage University Partners, DUMAC, and the Longevity Fund also participated in the round.

The funding will be used to further the company’s product development efforts based on its ARCUS® genome editing platform. More information about Precision Biosciences’ $110 million Series B financing can be obtained from their press release.

The Fenwick transaction team was led by intellectual property attorneys Daniel Becker, Kevin Kabler, Danni Sun, and Mayim Wiens.